{"result": "(\"entity\"<|>DANIEL ANTONIO DE LUIS ROMÁN<|>PERSON<|>Daniel Antonio de Luis Román is a contributor to the research on immunonutrition in artificial nutritional support.)\n##\n(\"entity\"<|>EMILIA GÓMEZ HOYOS<|>PERSON<|>Emilia Gómez Hoyos is a contributor to the research on immunonutrition in artificial nutritional support.)\n##\n(\"entity\"<|>JUAN JOSÉ LÓPEZ GÓMEZ<|>PERSON<|>Juan José López Gómez is a contributor to the research on immunonutrition in artificial nutritional support.)\n##\n(\"entity\"<|>ANA ORTOLÁ BUIGES<|>PERSON<|>Ana Ortolá Buiges is a contributor to the research on immunonutrition in artificial nutritional support.)\n##\n(\"entity\"<|>BEATRIZ TORRES TORRES<|>PERSON<|>Beatriz Torres Torres is a contributor to the research on immunonutrition in artificial nutritional support.)\n##\n(\"entity\"<|>CENTRO DE INVESTIGACIÓN DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>ORGANIZATION<|>The Centro de Investigación de Endocrinología y Nutrición is a research center focused on endocrinology and nutrition.)\n##\n(\"entity\"<|>HOSPITAL CLÍNICO UNIVERSITARIO<|>ORGANIZATION<|>The Hospital Clínico Universitario in Valladolid is a clinical hospital where research and treatment in endocrinology and nutrition are conducted.)\n##\n(\"entity\"<|>VALLADOLID<|>GEO<|>Valladolid is a city in Spain where the research and clinical activities related to immunonutrition are taking place.)\n##\n(\"entity\"<|>INMUNONUTRICIÓN<|>EVENT<|>Immunonutrition refers to the study and application of nutritional support that influences the immune response in patients.)\n##\n(\"relationship\"<|>DANIEL ANTONIO DE LUIS ROMÁN<|>CENTRO DE INVESTIGACIÓN DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Daniel Antonio de Luis Román is associated with the Centro de Investigación de Endocrinología y Nutrición as a contributor to research<|>7)\n##\n(\"relationship\"<|>EMILIA GÓMEZ HOYOS<|>CENTRO DE INVESTIGACIÓN DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Emilia Gómez Hoyos is associated with the Centro de Investigación de Endocrinología y Nutrición as a contributor to research<|>7)\n##\n(\"relationship\"<|>JUAN JOSÉ LÓPEZ GÓMEZ<|>CENTRO DE INVESTIGACIÓN DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Juan José López Gómez is associated with the Centro de Investigación de Endocrinología y Nutrición as a contributor to research<|>7)\n##\n(\"relationship\"<|>ANA ORTOLÁ BUIGES<|>CENTRO DE INVESTIGACIÓN DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Ana Ortolá Buiges is associated with the Centro de Investigación de Endocrinología y Nutrición as a contributor to research<|>7)\n##\n(\"relationship\"<|>BEATRIZ TORRES TORRES<|>CENTRO DE INVESTIGACIÓN DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Beatriz Torres Torres is associated with the Centro de Investigación de Endocrinología y Nutrición as a contributor to research<|>7)\n##\n(\"relationship\"<|>DANIEL ANTONIO DE LUIS ROMÁN<|>HOSPITAL CLÍNICO UNIVERSITARIO<|>Daniel Antonio de Luis Román is associated with the Hospital Clínico Universitario for clinical research<|>7)\n##\n(\"relationship\"<|>EMILIA GÓMEZ HOYOS<|>HOSPITAL CLÍNICO UNIVERSITARIO<|>Emilia Gómez Hoyos is associated with the Hospital Clínico Universitario for clinical research<|>7)\n##\n(\"relationship\"<|>JUAN JOSÉ LÓPEZ GÓMEZ<|>HOSPITAL CLÍNICO UNIVERSITARIO<|>Juan José López Gómez is associated with the Hospital Clínico Universitario for clinical research<|>7)\n##\n(\"relationship\"<|>ANA ORTOLÁ BUIGES<|>HOSPITAL CLÍNICO UNIVERSITARIO<|>Ana Ortolá Buiges is associated with the Hospital Clínico Universitario for clinical research<|>7)\n##\n(\"relationship\"<|>BEATRIZ TORRES TORRES<|>HOSPITAL CLÍNICO UNIVERSITARIO<|>Beatriz Torres Torres is associated with the Hospital Clínico Universitario for clinical research<|>7)\n##\n(\"relationship\"<|>VALLADOLID<|>HOSPITAL CLÍNICO UNIVERSITARIO<|>The Hospital Clínico Universitario is located in Valladolid, Spain<|>8)\n##\n(\"relationship\"<|>INMUNONUTRICIÓN<|>DANIEL ANTONIO DE LUIS ROMÁN<|>Daniel Antonio de Luis Román is involved in research related to immunonutrition<|>6)\n##\n(\"relationship\"<|>INMUNONUTRICIÓN<|>EMILIA GÓMEZ HOYOS<|>Emilia Gómez Hoyos is involved in research related to immunonutrition<|>6)\n##\n(\"relationship\"<|>INMUNONUTRICIÓN<|>JUAN JOSÉ LÓPEZ GÓMEZ<|>Juan José López Gómez is involved in research related to immunonutrition<|>6)\n##\n(\"relationship\"<|>INMUNONUTRICIÓN<|>ANA ORTOLÁ BUIGES<|>Ana Ortolá Buiges is involved in research related to immunonutrition<|>6)\n##\n(\"relationship\"<|>INMUNONUTRICIÓN<|>BEATRIZ TORRES TORRES<|>Beatriz Torres Torres is involved in research related to immunonutrition<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: EN Board of Directors and the Clinical Guideli-        Wiley & Sons, Ltd.\n    nes Task force. Guidelines for the use of parenteral 29. Pironi L, Arends J, Bozzetti F, Cuerda C, Gillanders\n    and enteral nutrition in adult and pediatric pa-          L, Jeppesen PB, et al. Espen guidelines on chronic\n    tients. JPEN 2002; 26:1SA-138SA.                          intestinal failure in adults. Clin Nutr 2016; 35:\n25. Mermel LA, Farr BM, Sherertz RJ et al. Guidelines for     247-307.\n    the management of intravascular catheter-related    30. ASPEN Board of Directors and the Clinical Guideli-\n    infections. Clin Infect Dis. 2001; 32:1249-72.            nes Task force. Guidelines for the use of parenteral\n26. Mermel LA. Prevention of intravascular catheter-rela-     and enteral nutrition in adult and pediatric pa-\n    ted infections. Ann Intern Med. 2000; 132:391-402.        tients. JPEN 2002; 26(supl 1): 1SA-138SA.\n---\nThe image appears to be a blank white page. There is no visible content, text, diagrams, or any other information present in this image. Therefore, I cannot provide any markdown translation or description of content, as there is nothing to transcribe or describe.\n---\n# Tema 50.\n## Inmunonutrición en el soporte nutricional artificial\n\nDaniel Antonio de Luis Román\nEmilia Gómez Hoyos\nJuan José López Gómez\nAna Ortolá Buiges\nBeatriz Torres Torres\nCentro de Investigación de Endocrinología y Nutrición. Facultad de Medicina.\nServicio de Endocrinología y Nutrición. Hospital Clínico Universitario. Valladolid\n\nDietoterapia, nutrición clínica y metabolismo. Tercera edición. Copyright 2017 de los autores, SEEN y Grupo Aula Médica.\nTodos los derechos reservados. Páginas 789-798.\n\n1. Introducción\n2. Fisiopatología\n3. Implicaciones clínicas de fórmulas inmunomoduladoras\n4. Futuros inmunonutrientes\n5. Resumen\n6. Bibliografía\n\n### 1. Introducción\n\nNuestro estado nutricional y nuestro estado inmunológico están relacionados, por ello en un paciente desnutrido la respuesta inmunológica está disminuida, y ante un cuadro de inflamación aguda y/o crónica el gasto energético y la situación nutricional se alteran¹.\n\nSi analizamos las diferentes barreras defensivas que tenemos ante la agresión externa, observaremos cómo la desnutrición puede incidir en todas ellas. De este modo, nuestras mucosas y piel pueden afectarse con atrofias y úlceras ante un estado de malnutrición. También se deterioran la inmunidad humoral y celular. La inmunidad humoral se ve afectada en pacientes malnutridos al afectarse los linfocitos T cooperadores. La inmunidad celular se afecta en la desnutrición con disminución del tamaño del timo y alteración del cociente CD8/CD4². La respuesta del organismo ante la agresión es muy compleja y por tanto incidirá en la situación nutricional, fundamentalmente el sistema inmune responde con dos componentes. Se activan los linfocitos T y B y se inicia una respuesta inflamatoria mediante citoquinas, interleucina 1 (IL-1), interleucina-6 (IL-6) y factor de necrosis tumoral alfa (TNF-alfa). Estas citoquinas aumentan el catabolismo de las proteínas y las grasas para enviar nutrientes al sistema inmune³. Sin embargo, se produce una gran diversidad de mediadores como citoquinas antinflamatorias, factores de crecimiento, óxido nítrico, eicosanoides y radicales libres, influyendo todos ellos en la respuesta ante la agresión.\n\nNo debemos olvidar que la síntesis de mediadores de la inflamación-agresión presenta un curso temporal corto y que va a producir la activación de determinados genes que aumentan en el tiempo la respuesta. De este modo se activa el factor nuclear kappa beta (NFkB) y la proteína activadora -1, por ejemplo la activación del NFkB se ha relacionado en pacientes con sepsis con mayor mortalidad. En este punto es donde aparece alguno de los efectos de los nutrientes con actividad inmunomoduladora, así los antioxidantes y los ácidos grasos omega-3 son capaces de disminuir la activación de NFkB. En la tabla 1 se resume el mecanismo de acción de diferentes inmunonutrientes que podemos encontrar en las fórmulas nutricionales.\n\nPor tanto, la situación nutricional de un paciente incide sobre su situación inmunológica. Pero cabría preguntarnos si el soporte nutricional de un paciente puede incidir sobre su situación inmunológica y por tanto sobre la morbimortalidad asociada a\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}